{
  "id": 4680454,
  "title": "Lilly to Buy Merida for $2.88 Billion in Autoimmune Push",
  "url": "https://urgent.news/2026/08/31/lilly-to-buy-merida-for-2-88-billion-in-autoimmune-push",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T17:07:31.000Z",
  "source": {
    "name": "Bloomberg",
    "slug": "bloomberg",
    "url": "https://www.bloomberg.com/news/videos/2026-08-31/lilly-to-buy-merida-for-2-88-billion-in-autoimmune-push-video"
  },
  "original_language": "en",
  "account": null,
  "summary": "Bloomberg reports that Eli Lilly & Co. is set to acquire Merida Biosciences Inc. for up to $2.88 billion in cash, signaling the company's expansion into the autoimmune and allergic diseases sector. This move is part of Lilly's broader strategy to diversify beyond its successful weight-loss and diabetes markets, aiming to develop the next blockbuster medicine. The acquisition comes as Lilly has been aggressively expanding its pipeline through a series of record-breaking deals totaling over $20 billion in 2026, leveraging the revenue from its Zepbound and Mounjaro drugs to fuel these strategic investments.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}